bluebird bio Inc (BLUE) : Artal Group S.a. reduced its stake in bluebird bio Inc by 14.44% during the most recent quarter end. The investment management company now holds a total of 385,000 shares of bluebird bio Inc which is valued at $24,120,250 after selling 65,000 shares in bluebird bio Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.bluebird bio Inc makes up approximately 0.62% of Artal Group S.a.’s portfolio.
Other Hedge Funds, Including , Pacad Investment Ltd. sold out all of its stake in BLUE during the most recent quarter. The investment firm sold 13,200 shares of BLUE which is valued $826,980.California State Teachers Retirement System boosted its stake in BLUE in the latest quarter, The investment management firm added 800 additional shares and now holds a total of 78,487 shares of bluebird bio Inc which is valued at $4,128,416. bluebird bio Inc makes up approx 0.01% of California State Teachers Retirement System’s portfolio. Sandy Spring Bank sold out all of its stake in BLUE during the most recent quarter. The investment firm sold 660 shares of BLUE which is valued $29,634.Taylor Wealth Management Partners boosted its stake in BLUE in the latest quarter, The investment management firm added 24,810 additional shares and now holds a total of 24,910 shares of bluebird bio Inc which is valued at $1,281,620. bluebird bio Inc makes up approx 0.59% of Taylor Wealth Management Partners’s portfolio.California Public Employees Retirement System reduced its stake in BLUE by selling 5,600 shares or 6.5% in the most recent quarter. The Hedge Fund company now holds 80,600 shares of BLUE which is valued at $4,203,290. bluebird bio Inc makes up approx 0.01% of California Public Employees Retirement System’s portfolio.
bluebird bio Inc opened for trading at $62.15 and hit $63.1687 on the upside on Monday, eventually ending the session at $62, with a gain of 0.57% or 0.35 points. The heightened volatility saw the trading volume jump to 9,27,519 shares. Company has a market cap of $2,313 M.
On the company’s financial health, bluebird bio Inc reported $-2.07 EPS for the quarter, missing the analyst consensus estimate by $ -0.48 based on the information available during the earnings call on Nov 2, 2016. Analyst had a consensus of $-1.59. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $1.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.18 EPS.
Many Wall Street Analysts have commented on bluebird bio Inc. bluebird bio Inc was Downgraded by Cantor Fitzgerald to ” Sell” on Oct 14, 2016. Company shares were Reiterated by Leerink Partners on Oct 14, 2016 to “Outperform”, Firm has raised the Price Target to $ 80 from a previous price target of $67 .ROTH Capital Resumed bluebird bio Inc on Sep 22, 2016 to “Buy”, Price Target of the shares are set at $87.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.